MAPT and supranuclear palsy, progressive, 1: AD fluid markers (CSF p-tau, Aβ-40, and serum p-tau217) may modulate the clinical presentation of PSP/CBS [123], while tau-PET and plasma NfL show clinical progression of CI in patients with Aβ-negative CBS [204].